Raymond James Financial Services Advisors Inc. Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

Raymond James Financial Services Advisors Inc. grew its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 5.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 273,593 shares of the company's stock after purchasing an additional 13,133 shares during the quarter. Raymond James Financial Services Advisors Inc.'s holdings in Eli Lilly and Company were worth $212,844,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company during the third quarter worth approximately $27,000. Tidemark LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at $29,000. Core Wealth Advisors Inc. lifted its holdings in Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company's stock valued at $29,000 after purchasing an additional 32 shares in the last quarter. Finally, Legacy Financial Group LLC acquired a new stake in Eli Lilly and Company during the 3rd quarter worth $35,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business's stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a "neutral" rating in a research report on Thursday, April 11th. Citigroup increased their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a "buy" rating in a report on Tuesday, April 2nd. Wells Fargo & Company boosted their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an "overweight" rating in a report on Tuesday, February 6th. Truist Financial reaffirmed a "buy" rating and issued a $850.00 price target on shares of Eli Lilly and Company in a report on Friday, March 22nd. Finally, TheStreet raised Eli Lilly and Company from a "c+" rating to a "b" rating in a research note on Friday, March 8th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average target price of $731.55.

Eli Lilly and Company Trading Up 6.0 %

Shares of NYSE:LLY traded up $44.36 during mid-day trading on Tuesday, reaching $781.56. 7,432,651 shares of the company were exchanged, compared to its average volume of 3,071,009. Eli Lilly and Company has a 1 year low of $392.26 and a 1 year high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The firm's 50-day simple moving average is $761.41 and its 200 day simple moving average is $669.21. The firm has a market cap of $742.61 billion, a price-to-earnings ratio of 134.75, a P/E/G ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts' consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion for the quarter, compared to analysts' expectations of $8.95 billion. During the same period in the prior year, the firm earned $2.09 earnings per share. The firm's revenue was up 28.1% compared to the same quarter last year. Equities research analysts forecast that Eli Lilly and Company will post 12.51 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.